48% of People Experience Constant Pain, 34% of Those Rates Their Pain as Very Severe, And 59% of Those with Constant Pain Say It Is Not Under Control.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c39751) has announced the addition of "Pain Therapeutics: New Times, New Targets" to their offering.

This new Pain Therapeutics market analysis report focuses on new advances in drug discovery and development. The report provides a background on pain, current therapies and research and development in the area. Profiles of companies with major pain programs include Abbott Laboratories, AstraZeneca, GlaxoSmithKline, GW Pharmaceuticals, Johnson & Johnson, Merck & Co., Neuromed Pharmaceuticals, Novartis, Pfizer, Vernalis, VistaGen Therapeutics, Xenome and more. In-depth interviews with industry leaders provide specific case studies from both biotech and academia that give a sense of what's really going on in the trenches.

Pain affects all of us sometimes, and many of us all the time; yet the pharmacologic therapies available to alleviate pain have changed surprisingly little in the last fifty years. Those of us who suffer from acute pain originating in the peripheral nervous system have the best chances of finding relief, while others suffering chronic neuropathic pain must often settle for partial, or even minimal, relief. Results from a 2004 survey of chronic pain sufferers are enlightening: 48% experience constant pain, 34% of those rate their pain as very severe, and 59% of those with constant pain say it is not under control.

In the four years that have elapsed since we published the last edition of Pain Therapeutics, sufficient progress in drug discovery and development has been made to justify the subtitle for this current edition: New Times, New Targets. Although the non-steroidal anti-inflammatory drug (NSAID) field took a mighty blow from problems with COX-2 inhibitors, and a number of compounds once thought promising have failed to make it through the pipeline, some promising contenders remain standing, and several highly promising new drug targets have emerged in recent years.

This fourth edition of Pain Therapeutics is offered in order to:

--Provide background information sufficient for general readers to understand the remainder of the report.

--Review the current state of the pain therapeutics field.

--Survey current pharmacologic research and development for pain indications.

--Examine market trends and prospects.

--Profile companies active in the field.

--Provide perspective in the form of interviews with experts in the field.

Key Topics Covered Include:

--History of Pain Therapeutics

--Current Status of Pain Therapeutics

--Current Pain Research and Development .

--Pain Therapy Market Dynamics

--Company Profiles

--Interviews with Industry Experts

Companies Mentioned Include:

- Abbott Laboratories

- Acadia Pharmaceuticals

- Adolor Corporation

- AstraZeneca

- CeNeS Pharmaceuticals plc

- Cognetix, Inc

- Corgentech Inc

- GlaxoSmithKline

- GW Pharmaceuticals

- Johnson & Johnson

- Merck & Co., Inc

- NeurogesX, Inc

- Neuromed Pharmaceuticals Inc

- NeuroTargets Ltd

- Novartis

- PainCeptor Pharma Corp

- Pain Therapeutics, Inc 

- Pfizer, Inc

- Pharmos Corporation

- Renovis, Inc

- Rinat Neuroscience Corp

- Synt:em

- Vernalis

- VistaGen Therapeutics, Inc

- Xenome Ltd

For more information visit http://www.researchandmarkets.com/reports/c39751